Valuations are always a popular topic. With much discussion about whether we are at the bottom of the current cycle, John Glencross, CEO and Co-Founder of Calculus Capital, who has experienced multiple economic cycles, speaks to Brian Moretta.
Calculus backs the innovators, the experts and the game changers across the fastest growing sectors in the UK – technology, healthcare and the creative industries.
We focus on companies driving innovation, advancing healthcare and creating jobs and opportunities throughout the country.
MIP’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients.
Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024.
Tagomics, developers of a cutting-edge platform for comprehensive disease insight and diagnosis, today announces a £6.7m funding round. This achievement follows a £1.6m pre-seed round led by IQ Capital and Start Codon and including grant funding from Innovate UK. The investment will accelerate Tagomics’ scientific research and product development, with the goal of delivering improvements … Continued